Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies - Wikidata - wikimedia - TriplyDB

Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies

Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies

http://www.wikidata.org/entity/Q35003605

about

PPAR-γ2 and PTPRD gene polymorphisms influence type 2 diabetes patients' response to pioglitazone in China.In vitro analysis and quantitative prediction of efavirenz inhibition of eight cytochrome P450 (CYP) enzymes: major effects on CYPs 2B6, 2C8, 2C9 and 2C19 Human liver expression of CYP2C8: gender, age, and genotype effects.Rocuronium blockade reversal with sugammadex vs. neostigmine: randomized study in Chinese and Caucasian subjects.Cerivastatin in vitro metabolism by CYP2C8 variants found in patients experiencing rhabdomyolysis Targeting of splice variants of human cytochrome P450 2C8 (CYP2C8) to mitochondria and their role in arachidonic acid metabolism and respiratory dysfunction.Pharmacogenetics in Jewish populations.Cytochrome P450 single nucleotide polymorphisms in an indigenous Tanzanian population: a concern about the metabolism of artemisinin-based combinations.Gender-Specific Effect of CYP2C8*3 on the Risk of Essential Hypertension in Bulgarian Patients.Drug metabolism by CYP2C8.3 is determined by substrate dependent interactions with cytochrome P450 reductase and cytochrome b5.Metabolic capabilities of cytochrome P450 enzymes in Chinese liver microsomes compared with those in Caucasian liver microsomes.Preemptive Genotyping of CYP2C8 and CYP2C9 Allelic Variants Involved in NSAIDs Metabolism for Sickle Cell Disease Pain Management Genetic polymorphisms of CYP2C8 in the Czech Republic Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes.Pharmacogenetics of analgesic drugs Impact of the CYP2C8 *3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone.Analysis of the Functional Polymorphism in the Cytochrome P450 CYP2C8 Gene rs11572080 with Regard to Colorectal Cancer Risk.Genetic determinants of mycophenolate-related anemia and leukopenia after transplantation.Influence of CYP2C8*2 on the pharmacokinetics of pioglitazone in healthy African-American volunteers Frequencies of Cytochrome P450 2B6 and 2C8 Allelic Variants in the Mozambican Population.The influence of CYP2C8*3 on carbamazepine serum concentration in epileptic pediatric patients.Current clinical evidence on pioglitazone pharmacogenomics.Introducing New Antimalarial Analogues of Chloroquine and Amodiaquine: A Narrative Review.Personalized therapy in pain management: where do we stand?Pharmacogenetics and individualized therapy in children: immunosuppressants, antidepressants, anticancer and anti-inflammatory drugs.An update on ethnic differences in drug metabolism and toxicity from anti-cancer drugs.Cytochrome P450 variations in different ethnic populations.PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8.Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions.A Review of Pharmacogenetics of Antimalarials and Associated Clinical Implications.How polymorphisms of the cytochrome P450 genes affect ibuprofen and diclofenac metabolism and toxicity.In Vitro and In Vivo Drug-Drug Interaction Studies to Assess the Effect of Abiraterone Acetate, Abiraterone, and Metabolites of Abiraterone on CYP2C8 Activity.Peroxisome proliferator-activated receptor alpha, PPARα, directly regulates transcription of cytochrome P450 CYP2C8.Comparison of genetic variation in drug ADME-related genes in Thais with Caucasian, African and Asian HapMap populations.Impact of CYP2C8*3 polymorphism on in vitro metabolism of imatinib to N-desmethyl imatinib.CYP2C19*17 gain-of-function polymorphism is associated with peptic ulcer disease.Distribution of CYP2C8 and CYP2C9 amino acid substitution alleles in South Indian diabetes patients: A genotypic and computational protein phenotype study.Analysis of a gene panel for targeted sequencing of colorectal cancer samples.Identification of genetic variants in pharmacokinetic genes associated with Ewing Sarcoma treatment outcome.Toward reduction in animal sacrifice for drugs: molecular modeling of Macaca fascicularis P450 2C20 for virtual screening of Homo sapiens P450 2C8 substrates.

P2860

Q33572403-8E98CF6B-175E-4602-868D-9345F0B67F41 Q33821729-04D61417-858A-445D-98F4-C96183864BB6 Q33891033-15E55655-AB45-4AE9-954C-FE818F6AE4DD Q34125680-052B1030-730F-4D2D-8BEC-91BE9FCB6605 Q34360732-69374459-0E7A-4306-B120-F1DB1175FF05 Q34396767-AEC075FF-D53B-480A-B8E2-FAB438BEA0D8 Q34458720-B4F2AD95-C6E2-4BD3-9952-5F6EA35B96BF Q34491448-FE214975-01E2-4E73-8F3F-75C71D20795D Q34495642-D5498FFF-A894-4F45-B2C0-20A1210ECE80 Q35175018-A0C953F6-09AE-478E-817B-ED7D6C354CB2 Q35718630-9F441BA4-CEF7-4C5F-835A-6A67A765531A Q35909069-6415FC48-5959-4DCF-8E67-57F5EF43ED7F Q36092754-DECAFDAA-7E0E-478C-927E-71F8D4A90CD9 Q36094919-2BCAB90A-7B54-4B45-ABB3-83640EF1218C Q36110592-65961909-CE45-46EF-8300-A400788077A3 Q36562502-3B4AE4C1-7742-4090-BE35-644940171832 Q36611264-6537B112-F861-4DEA-B936-3F97E1D5EFD1 Q37013588-CBDE2620-512E-4015-888A-138979D819DA Q37141923-63DD3AEB-8FD1-497E-AC48-692FE6D62DF1 Q37171678-6AD1A485-66F0-4128-B2C8-DA9DBCD5260E Q37262064-EEE70A3F-5E22-44F2-ACB9-911BA9F7CC55 Q37342358-49BC4865-D8CC-410E-9CCC-F5626643A9A0 Q37721293-AC687D14-BBF4-46D6-B1E0-89AC8E70A40C Q37760955-F7781DB0-10C0-4D88-B52C-7997E60594D0 Q37892531-575D00D7-D737-490F-984E-EB991FBA6DDA Q37939200-72E07AEC-A788-4EB3-9727-A78E8413EBEF Q37979866-2714162F-F5DE-4B24-9F25-E857F3830111 Q38130410-7CA267CC-E8BF-4597-9B1E-55C30D404F8A Q38684505-1496B98F-1517-45DA-80DB-69C46BA54E3B Q38772466-2E465265-0179-41F4-B254-5FDDBD3C816C Q38811685-B89F4267-B6F6-47B8-8AF9-E21A03340471 Q39509370-CA9C7E96-2E18-498B-B47D-CC6B933C42C8 Q40305168-EEB27ACD-9A43-4592-BB96-24D9439E3F8D Q40480835-F5CBE1E2-D4AE-4AA6-A5BC-B4AF183165DE Q40751644-9C6E73CA-B0A5-4A2D-923C-24DFD2357BB4 Q45179286-4BB8FB5E-345D-4F50-96DE-17F4AF1FDC1D Q48058245-A68A14EA-6EB0-49C7-B8D2-DCE022C48399 Q50420743-BBED0DBA-4561-43CE-8282-567D81D106AF Q50858643-7F7DEE80-3BA0-4D33-9FA1-B0E426C09774 Q51068004-FB845FCE-9F44-4DCC-A648-876E3E24ABB7

P2860

Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies

http://www.wikidata.org/entity/Q35003605

description

2009 nî lūn-bûn

@nan

2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies

@ast

Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies

@en

type

label

Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies

@ast

Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies

@en

prefLabel

Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies

@ast

Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies

@en

P1433

Q35003605-8E16D06E-2C44-4948-BF29-965349CF22B1

P1476

Q35003605-CF3D70B3-30B8-4775-8501-E67737AA7094

P2093

Q35003605-AE12B5BA-C292-4ED9-B88E-5561E93EF7F1

Q35003605-CC47F4AF-69BD-4E17-A339-8BAF045749B1

P2860

Q35003605-01E732AB-9964-48BA-9D7C-EB50F01E1A39

Q35003605-06503A08-5BBB-445C-BBAA-6C731A471103

Q35003605-0979DA4A-81F8-49E9-9C79-256D99403353

Q35003605-09EA272E-1DB3-40B4-805C-BF4C04ECEA17

Q35003605-0DCA097E-EF3E-4E2E-B7F2-2B11C862E88F

Q35003605-116F13CF-256E-49BC-AFBE-FBCF1BAF3472

Q35003605-120E823E-DC8E-4EB1-8C6C-EB30F6E0DC62

Q35003605-16A7CB37-252D-4235-9629-8A07CF3292C8

Q35003605-185A0D47-16B2-47B5-8CC3-E9C5F5E19C12

Q35003605-1B774D0B-9E06-47EA-8EB8-9EC3843BF72B

P304

Q35003605-2B79A1D3-B098-497E-A536-DA6EDCD27212

P31

Q35003605-7C6FE78F-61CF-4B2C-A761-9D6809C5E5CF

P356

Q35003605-EC0C7EA4-C6CE-4C7F-8922-EFDA4E2B2E7D

P433

Q35003605-D582EBA3-C86C-4A6A-82D1-C2E1F13F3537

P478

Q35003605-6E5CD8E6-7287-420A-93D5-42D4651B2285

P577

Q35003605-DD729E1A-A6D5-41E0-A1F2-6DCAA97DE30C

P5875

Q35003605-533F9CC1-07C3-48F3-9A3C-8DF06977E015

P698

Q35003605-DF545ACD-3B43-40BE-8AFF-C5951A8EEC00

P932

Q35003605-A15BDC1F-5D61-46AC-97BC-4C77C5CE8D17

P356

P1433

Pharmacogenomics

P1476

Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies

@en

P2093

Christina L Aquilante

http://www.w3.org/2001/XMLSchema#string

Elizabeth B Daily

http://www.w3.org/2001/XMLSchema#string

P2860

Structure of human microsomal cytochrome P450 2C8. Evidence for a peripheral fatty acid binding site

Determinants of Cytochrome P450 2C8 Substrate Binding: STRUCTURES OF COMPLEXES WITH MONTELUKAST, TROGLITAZONE, FELODIPINE, AND 9-CIS-RETINOIC ACID

Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs

Cytochrome P450 2C8 and flavin-containing monooxygenases are involved in the metabolism of tazarotenic acid in humans

High-dose paclitaxel in combination with doxorubicin, cyclophosphamide and peripheral blood progenitor cell rescue in patients with high-risk primary and responding metastatic breast carcinoma: toxicity profile, relationship to paclitaxel pharmacoki

Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes

SLCO1B1 variants and statin-induced myopathy--a genomewide study

Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1.

Clinical pharmacokinetics and drug metabolism of tazarotene: a novel topical treatment for acne and psoriasis.

Cytochrome P-450 3A4 and 2C8 are involved in zopiclone metabolism.

P304

1489-1510

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/PGS.09.82

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2009-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26819005

http://www.w3.org/2001/XMLSchema#string

P698

19761371

http://www.w3.org/2001/XMLSchema#string

P932

2778050

http://www.w3.org/2001/XMLSchema#string